NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

flipper44,

That change at or near the time of progression to mesenchymal phenotype and Dr. Linda Liau's observations over time with regard to DC treatment effectiveness on this subtype was part of the early digging that strengthened my confidence that NWBO was on to something. I believe that about 80-85% of GBM progresses to mesenchymal phenotype. As you have stated, not all biomarkers will become mesenchymal type but many of those targets will appear and become susceptible to treatment including migratory cancer cells, which are also mesenchymal.